je.st
news
Actinium Completes Technology Transfer For Manufacturing Of Its Lead Drug Candidate Iomab-B
2013-12-30 05:54:18| drugdiscoveryonline Home Page
Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has successfully transferred the technology for the manufacture of Iomab-B (BC8-I-131), a drug being developed for therapeutic treatment of incurable blood cancers
Tags: technology
lead
transfer
drug
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||